NCT03485274

Substance Misuse To Psychiatric Disorders for Cannabis

Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 16 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Conditions

• Cannabis Use Disorder
• Depressive State
• Anxiety State
• Depression
• Anxiety Disorders
• Pharmacotherapy

Interventions

Type	Name	Description
DRUG	Vortioxetine	oral medication taken once daily
OTHER	Treatment as Usual	Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine

Timeline

• Start date: 2018-07-25
• Primary completion: 2023-02-28
• Completion: 2023-04-30
• First posted: 2018-04-02
• Last updated: 2023-07-05

Locations

1 site across 1 country: Hong Kong

Regulatory

• FDA-regulated drug study